These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32155362)

  • 21. Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements.
    Hong YH; Dublin N; Razack AH; Mohd MA; Husain R
    Urology; 2010 Jun; 75(6):1294-8. PubMed ID: 19914693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of urinary stones on the composition of a 24-hour urine sample.
    Laube N; Pullmann M; Hergarten S; Hesse A
    Clin Chem; 2003 Feb; 49(2):281-5. PubMed ID: 12560352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium oxalate crystallization properties in urine with different specific electrical conductivities.
    Tiselius HG
    J Urol; 1992 Sep; 148(3 Pt 2):990-4. PubMed ID: 1507357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study on nano- and microcrystallites in the urines of calcium oxalate stone formers].
    Huang ZJ; Li JJ; He JY; Ouyang JM
    Guang Pu Xue Yu Guang Pu Fen Xi; 2010 Jul; 30(7):1913-7. PubMed ID: 20827998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Plasma Oxalate in Relation to eGFR in Patients with Primary Hyperoxaluria, Enteric Hyperoxaluria and Urinary Stone Disease.
    Assimos DG
    J Urol; 2018 Apr; 199(4):887. PubMed ID: 29642351
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton.
    Erwin DT; Kok DJ; Alam J; Vaughn J; Coker O; Carriere BT; Lindberg J; Husserl FE; Fuselier H; Cole FE
    Am J Kidney Dis; 1994 Dec; 24(6):893-900. PubMed ID: 7985666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Urinary material affecting calcium oxalate monohydrate stone formation].
    Shirane Y; Yamamoto A; Mizuta K; Hiraishi K; Kurokawa K; Kagawa S
    Nihon Hinyokika Gakkai Zasshi; 1989 Jul; 80(7):995-9. PubMed ID: 2607720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis].
    Kustov AV; Strelnikov AI; Moryganov MA; Airapetyan AO; Smirnov PR; Lyalyakina EV; Toms SR
    Urologiia; 2017 Sep; (4):22-26. PubMed ID: 28952687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of urinary macromolecules on the nucleation of calcium oxalate in idiopathic stone formers and healthy controls.
    Borghi L; Meschi T; Guerra A; Bergamaschi E; Mutti A; Novarini A
    Clin Chim Acta; 1995 Jul; 239(1):1-11. PubMed ID: 7586581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers.
    Fuselier HA; Moore K; Lindberg J; Husserl FE; Cole FE; Kok DJ; Whitehead D; Galliano DJ; Erwin DT
    Urology; 1998 Dec; 52(6):988-94. PubMed ID: 9836542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients.
    Siener R; Glatz S; Nicolay C; Hesse A
    Eur Urol; 2003 Oct; 44(4):467-74. PubMed ID: 14499683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of calcium oxalate crystallization by urinary macromolecules.
    Bek-Jensen H; Tiselius HG
    Urol Res; 1991; 19(3):165-9. PubMed ID: 1887524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idiopathic calcium oxalate urinary lithiasis: usefulness of Parks' and Tiselius' indices in the evaluation of the risk of stone formation.
    Robert M; Roux JO; Boularan AM; Bourelly F; Monnier L; Grasset D
    Urol Int; 1995; 55(2):88-92. PubMed ID: 8533202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evening urinary oxalate excretion in stone formers.
    Banks JG; Sullivan M; Hargreave TB
    Br J Urol; 1979 Oct; 51(5):349-51. PubMed ID: 533589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.
    Borghi L; Guerra A; Meschi T; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Mar; 55(3):1041-50. PubMed ID: 10027942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental calcium oxalate stone formation with clinical application.
    PRIEN EL; GERSHOFF SN; ANDRUS SB
    Rein Foie; 1962 Jun; 4():II/155-62. PubMed ID: 14488758
    [No Abstract]   [Full Text] [Related]  

  • 37. Glycoprotein calcium oxalate crystal growth inhibitor in urine.
    Worcester EM; Nakagawa Y; Coe FL
    Miner Electrolyte Metab; 1987; 13(4):267-72. PubMed ID: 3306319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The oxalate-tolerance-value: a whole urine method to discriminate between calcium oxalate-stoneformers and others.
    Briellmann T; Hering F; Seiler H; Rutishauser G
    Urol Res; 1985; 13(6):291-5. PubMed ID: 4095828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 24 Hour urine metabolic differences between solitary and multiple stone formers: Results of the Collaboration on Urolithiasis in Pediatrics (CUP) working group.
    Saitz TR; Mongoue-Tchokote S; Sharadin C; Giel DW; Corbett S; Kovacevic L; Bayne AP;
    J Pediatr Urol; 2017 Oct; 13(5):506.e1-506.e5. PubMed ID: 28526618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of calcium phosphate crystalluria: influence of pH and osmolality and invariable presence of oxalate.
    Hallson PC; Rose GA
    Br J Urol; 1989 Nov; 64(5):458-62. PubMed ID: 2611613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.